Shots:

• The collaboration is a part of the planned P-III TRAILBLAZER-ALZ 3 trial of donanemab vs PBO in patients with cognitive & functional decline related to AD. The study will assess if therapy slows the clinical progression of AD
• Banner will support the enrollment of trial participants with & without e4 type of APOE4 gene through Alzheimer's Prevention Registry's GeneMatch program. Lilly will be sole sponsor of study and expect to start the enrollment in 2021
• Donanemab is an investigational Ab that targets a modified form of beta-amyloid. The therapy is being evaluated in the ongoing P-III TRAILBLAZER-ALZ 2 study for early- symptomatic AD

  Ref: PR Newswire | Image: Eli Lilly